Rocatinlimab: Data from P3 ROCKET-Horizon trial (NCT05651711) for moderate-to-severe atopic dermatitis in H2 2024 (Amgen) - Feb 7, 2024 - Q4 2023 Results: Initiation of P2 trial for asthma in H1 2024; Initiation of P3 trial for prurigo nodularis in H2 2024
New P2 trial • New P3 trial • P3 data • Asthma • Atopic Dermatitis • Immunology • Prurigo Nodularis
|